Consumer healthcare giant Kenvue has completed the global media and creative agency reviews it began three months ago, the company confirmed today.

As a result, the review process now formally draws to a close.

Publicis Media Assumes Expanded Responsibilities

Following the review, a company spokesperson confirmed that Publicis will lead media, commerce, healthcare professional engagement, and technology support.

In addition, Publicis will handle creative and production for the Neutrogena brand. Meanwhile, according to agency research firm COMvergence, the company spends an estimated $1.35 billion annually on measured media.

WPP Retains Creative Leadership Across Other Brands

At the same time, WPP will lead creative and production for all brands except Neutrogena.

Consequently, WPP continues to play a significant role across Kenvue’s broader brand portfolio.

Strategic Rationale Behind the Selection

Explaining the decision, the spokesperson said, “This powerful combination gives Kenvue the strongest blend of enduring creativity and modern precision to elevate brand building.”

Furthermore, the company expressed gratitude for the tremendous partnership of MediaSense, which supported the review, and acknowledged the exceptionally talented teams that participated in the pitch.

Changes from Previous Agency Arrangements

Previously, Interpublic, now part of Omnicom, served as the primary media incumbent, while Publicis Media handled the Asia-Pacific region. In parallel, creative incumbents included FCB, Deutsch, and Omnicom’s BBDO.

However, following Omnicom’s acquisition of IPG, FCB was retired as a go-to-market brand and folded into BBDO.

Kenvue’s Background and Brand Portfolio

Kenvue is the former consumer healthcare division of Johnson & Johnson, which spun the unit off in 2022. Today, its portfolio includes Tylenol, Band-aid, Listerine, Neutrogena, Aveeno, and more.